Lotta von Boehmer
Overview
Explore the profile of Lotta von Boehmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heikenwalder M, Federau C, von Boehmer L, Schwarz P, Wagner M, Zeller N, et al.
J Neuroimmunol
. 2024 Jun;
393:578399.
PMID: 38943763
No abstract available.
2.
Chowdhury R, Valainis J, Dubey M, von Boehmer L, Sola E, Wilhelmy J, et al.
Sci Immunol
. 2023 Mar;
8(81):eade3525.
PMID: 37000856
The response of gamma delta (γδ) T cells in the acute versus chronic phases of the same infection is unclear. How γδ T cells function in acute (Mtb) infection is...
3.
Yin Q, Yu W, Grzeskowiak C, Li J, Huang H, Guo J, et al.
Proc Natl Acad Sci U S A
. 2021 May;
118(21).
PMID: 34021082
Tumors are often infiltrated by T lymphocytes recognizing either self- or mutated antigens but are generally inactive, although they often show signs of prior clonal expansion. Hypothesizing that this may...
4.
Sebastian M, Schroder A, Scheel B, Hong H, Muth A, von Boehmer L, et al.
Cancer Immunol Immunother
. 2019 Feb;
68(5):799-812.
PMID: 30770959
CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa...
5.
Bengs S, Becker E, Busenhart P, Spalinger M, Raselli T, Kasper S, et al.
Int J Cancer
. 2019 Jan;
145(3):678-685.
PMID: 30653264
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This...
6.
von Boehmer L, Liu C, Ackerman S, Gitlin A, Wang Q, Gazumyan A, et al.
Nat Protoc
. 2016 Sep;
11(10):1908-1923.
PMID: 27658009
Methods to identify genes encoding immunoglobulin heavy and light chains from single B lymphocytes vary in efficiency, error rate and practicability. Here we describe a protocol to sequence and clone...
7.
Gristick H, von Boehmer L, West Jr A, Schamber M, Gazumyan A, Golijanin J, et al.
Nat Struct Mol Biol
. 2016 Sep;
23(10):906-915.
PMID: 27617431
HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). Variability in high-mannose and...
8.
Gitlin A, von Boehmer L, Gazumyan A, Shulman Z, Oliveira T, Nussenzweig M
Immunity
. 2016 Mar;
44(4):769-81.
PMID: 26944202
Somatic hypermutation (SHM) and class-switch recombination (CSR) increase the affinity and diversify the effector functions of antibodies during immune responses. Although SHM and CSR are fundamentally different, their independent roles...
9.
Gross S, Lennerz V, Gallerani E, Mach N, Bohm S, Hess D, et al.
Cancer Immunol Res
. 2015 Nov;
4(1):18-25.
PMID: 26563311
Previous cancer vaccination trials often aimed to activate CD8(+) cytotoxic T-cell (CTL) responses with short (8-10mer) peptides and targeted CD4(+) helper T cells (TH) with HLA class II-binding longer peptides...
10.
Dosenovic P, von Boehmer L, Escolano A, Jardine J, Freund N, Gitlin A, et al.
Cell
. 2015 Jun;
161(7):1505-15.
PMID: 26091035
A subset of individuals infected with HIV-1 develops broadly neutralizing antibodies (bNAbs) that can prevent infection, but it has not yet been possible to elicit these antibodies by immunization. To...